Almost all patients with a group of blood cancers called B-cell malignancies have two prominent "fingerprints" on the surface of leukemia and lymphoma cancers, called CD22 and CD19, Vallera explained.

Limited-stage, small-cell lung cancer (SCLC) treated with concurrent irinotecan-platinum. Background: SS1P is a recombinant immunotoxin, composed of an antimesothelin Fv fused to a 38 kDa fragment of ...

DT2219, a new bispecific ligand-directed diphtheria toxin, was found to be safe and clinically effective in a small group of patients with relapsed/refractory B-cell malignancies, according to phase I ...

Despite new treatment modalities, the clinical outcome in a substantial number of patients with multiple myeloma (MM) has yet to be improved. Antibody-based targeted therapies for myeloma patients ...

Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. Immunotoxins ...

A new immunotoxin works by getting shuttled into cancer cells and selectively destroying colon cancer, thanks to a quirk of biology. Colon cancer cells will gobble up poison if it's attached to a key ...

Delivering a targeted immunotoxin into breast ducts via openings in the nipple wiped out all visible and invisible precancerous lesions in laboratory studies, led by researchers at the Johns Hopkins ...

Chronic alcohol abuse and hepatitis can injure the liver and lead to fibrosis, the buildup of collagen and scar tissue. As a potential approach to treating liver fibrosis, University of California San ...

Global Immunotoxins Market · GlobeNewswire Inc. Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "Immunotoxins Market by Product, by Application, by End-User, and by Region" report has been added to ...

Almost all patients with a group of blood cancers called B-cell malignancies have two prominent "fingerprints" on the surface of leukemia and lymphoma cancers, called CD22 and CD19, Vallera explained.

Almost all patients with a group of blood cancers called B-cell malignancies have two prominent "fingerprints" on the surface of leukemia and lymphoma cancers, called CD22 and CD19, Vallera explained.